Pfizer shows profit growth from cost cuts and steadier COVID sales
By Bhanvi Satija and Michael Erman (Reuters) -Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine. Its COVID-19 vaccine, once a nearly $38 billion a year product, brought in …
Pfizer shows profit growth from cost cuts and steadier COVID sales Read More »








